{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marek RD"],"funding":["NCI NIH HHS","ZCH","NIH HHS"],"pagination":["1273"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11599078"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["<b>Background/Objectives</b>: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target this axis, many of these fail due to the emergent expression of AR RNA splice variants, such as AR-V7, that can signal independently of ligand binding. Other therapies, such as vaccination against prostate-specific antigens, have achieved FDA approvals but have fallen short of being incorporated as standard-of-care therapies for advanced prostate cancer. This may be due to the elevated level of immunosuppression observed in prostate cancer, which remains largely refractory to immune checkpoint blockade. <b>Methods</b>: We developed a "],"journal":["Vaccines"],"pubmed_title":["Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer."],"pmcid":["PMC11599078"],"funding_grant_id":["5T32-CA009111-45","T32 CA009111","5R01-CA23821","1R21CA274044-01","R21 CA274044"],"pubmed_authors":["Trotter TN","Chen M","Halabi S","Lei G","Yang X","Marek RD","Hartman ZC","Wang ME","Wang T","Lyerly HK","McBane J","Liu C","Wei J"],"additional_accession":[]},"is_claimable":false,"name":"Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.","description":"<b>Background/Objectives</b>: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target this axis, many of these fail due to the emergent expression of AR RNA splice variants, such as AR-V7, that can signal independently of ligand binding. Other therapies, such as vaccination against prostate-specific antigens, have achieved FDA approvals but have fallen short of being incorporated as standard-of-care therapies for advanced prostate cancer. This may be due to the elevated level of immunosuppression observed in prostate cancer, which remains largely refractory to immune checkpoint blockade. <b>Methods</b>: We developed a ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-19T17:35:04.151Z","creation":"2025-04-19T17:35:04.151Z"},"accession":"S-EPMC11599078","cross_references":{"pubmed":["39591176"],"doi":["10.3390/vaccines12111273"]}}